Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

First results of the What’s the STORY (Serum Testing Of Representative Youngsters) trial indicate higher resilience of children to COVID-19 compared to other respiratory illnesses.

Boy and girl playing piggyback rides. © Image by Pexels

What’s the STORY – a study run by the Oxford Vaccine Group in collaboration with Public Health England and funded by the National Institute for Health Research – investigates the prevalence of COVID-19 in children. Assessing the rates of coronavirus infection and immunity in children and teenagers will help to identify their role in spreading the disease, thus providing essential data for guiding governmental response to the pandemic.

The nationwide trial, commenced in February 2020, is led by Professor Matthew Snape from the Oxford Vaccine Group. As part of the study, OVG researchers assess the participants’ immunity by checking for coronavirus antibodies – the presence of which indicates that a child has already had COVID-19, even though they might not necessarily have shown symptoms.

Initial results of the trial show that between 3 and 4 percent of children in the study tested positive for antibodies – however, of those who tested positive, fewer than 10 percent showed any symptoms of COVID-19. The proportion of participants with detected antibodies was much higher in London than in other study sites.

These results suggest that although very few children and teenagers are experiencing COVID-19 symptoms, their infection rates are not that different from those seen in adults. Together with other studies this indicates COVID-19 does not spread readily via children, making it very different to other respiratory diseases, such as influenza. The finding “provides some reassurance when it comes to opening schools”, stated Professor Snape in an interview for BBC Newsnight.

More information about the study can be found on the What’s the STORY trial website, and the NIHR site.

Listen to Deb Cohen's interview with Professor Matthew Snape's on BBC Newsnight:

Similar stories

Oxford vaccine professor: rich countries have a moral duty to share their COVID-19 shots

COVID-19

Andrew Pollard writes about vaccine equity in his article for The Conversation.

Increasing vaccine uptake among ethnic minorities

COVID-19 Public Engagement

Dr Samantha Vanderslott and Dr Seilesh Kadambari discuss their collaborative approach to providing ethnic minority groups with information on vaccines.

COVID-19 elimination, not mitigation, best for health, economy and civil liberties – Oxford study

COVID-19

Countries which aimed to eliminate COVID-19 registered fewer deaths, better economic performance, and fewer restrictions and lockdowns, according to an article in The Lancet.

Alternating vaccines trial expands to include two additional vaccines

COVID-19

Researchers running the Com-Cov study, launched in February to investigate alternating doses of the Oxford-AstraZeneca vaccine and the Pfizer vaccine, have today announced that the programme will be extended to include the Moderna and Novavax vaccines in a new study.

UK and EU regulators conclude benefits of vaccination continue to outweigh the risks

COVID-19

Medical regulators in the UK and Europe have announced their conclusions from their reviews of very rare cases of unusual blood clots in people who have received the Oxford-AstraZeneca coronavirus vaccine.

Oxford University researchers release cheap, quick COVID-19 antibody test

COVID-19

The new easy-to-produce test detects coronavirus spike-protein binding antibodies in people who have tested positive for COVID-19.